Aytu BioPharma Q3 Revenue Climbs 18% to $4.7M on Exua Prescription Surge
Aytu BioPharma posted Q3 2026 revenue of $4.7 million, up 18% sequentially, driven by a 35% rise in Exua prescriptions. The net loss narrowed to $1.2 million as Exua’s improved product margins boosted overall profitability.
1. Q3 2026 Financial Performance
Aytu BioPharma reported Q3 revenue of $4.7 million, an 18% sequential increase fueled by Exua prescriptions rising 35%. Strong Exua uptake improved gross margins and narrowed the net loss to $1.2 million, reflecting early profitability trends from its flagship product.
Related News
SLAB
Silicon Labs SoC Powers 500,000 Wi-SUN Module Shipment for India Grid
SLAB•
RLAY
Relay Therapeutics Prices 22.9M Shares at $12 to Raise $275M
RLAY•
TOST
Toast Sponsors ICC UK Initiative, Showcases Platform Powering 171,000 Global Locations
TOST•
NVO
Novo Nordisk Shares Slump 45% to 10x P/E as Pharma Fuels Danish GDP
NVO•
GOOGL
Bill Ackman Cuts Alphabet Stake 95% to Fund Microsoft and Amazon Buys
GOOGL•
Sources
F